Oral thymic extract for chronic hepatitis C in patients previously treated with interferon: A randomized, double-blind, placebo-controlled trial

Robert S. Raymond, Michael B. Fallon, Gary A. Abrams

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Background: Hepatitis C is an important cause of chronic liver disease. It is claimed that Complete Thymic Formula, an over-the-counter herbal dietary supplement, is beneficial for patients with hepatitis C. Objective: To evaluate the efficacy and safety of Complete Thymic Formula. Design: Randomized, double-blind, placebo-controlled trial. Setting: Tertiary referral center. Patients: 38 patients with hepatitis C who did not respond to or were intolerant of interferon therapy. Intervention: Complete Thymic Formula for 3 to 6 months or placebo for 3 months. Measurements: Serial measurements of hepatitis C virus (HCV) RNA titers. Results: No differences were noted at 3 months between the placebo group (n=13) and the treatment group (n= 19) in mean HCV RNA titers (4.06 ± 1.52 x 106 copies/mL compared with 3.48 ± 1.92 x 106 copies/mL; P>0.2). The 19 patients who completed 6 months of treatment with Complete Thymic Formula remained positive for HCV, and their mean HCV RNA titers were similar at 6 months and at baseline (2.78 ± 1.96 x 106 copies/mL compared with 3.12 ± 1.94 X 106 copies/mL; P>0.2). Conclusions: Complete Thymic Formula did not benefit patients who had previously received interferon therapy. Patients should be advised about use of this over-the-counter compound.

Original languageEnglish (US)
Pages (from-to)797-800
Number of pages4
JournalAnnals of internal medicine
Volume129
Issue number10
DOIs
StatePublished - Nov 15 1998

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Oral thymic extract for chronic hepatitis C in patients previously treated with interferon: A randomized, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this